Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marzia Bonfanti

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|August 20, 2016
Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectivesDavide Croce, Marzia Bonfanti, Umberto Restelli
Global & Regional Health Technology Assessment|April 1, 2025
Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, et al.
Clinicoeconomics and Outcomes Research : CEOR|May 23, 2023
Co-Design as Enabling Factor for Patient-Centred Healthcare: A Bibliometric Literature ReviewSofia Silvola, Umberto Restelli, Marzia Bonfanti, et al.
Global & Regional Health Technology Assessment|May 22, 2025
Alessandro Tedesco, Marzia Bonfanti, Asia Barugolo, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 24, 2016
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in ItalyUmberto Restelli, Alfredo Alberti, Adriano Lazzarin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 25, 2020
Cost of illness of Primary Biliary Cholangitis - a population-based studyAlessio Gerussi, Umberto Restelli, Davide Croce, et al.
Therapeutics and Clinical Risk Management|July 20, 2017
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsUmberto Restelli, Giuliano Rizzardini, Andrea Antinori, et al.
Journal of Market Access & Health Policy|August 27, 2025
Pivotal Studies for Drugs About to Be Launched for Rare Diseases: Will They Better Support Health Technology Assessment and Market Access than in the Past?Claudio Jommi, Marzia Bonfanti, Melissa Guardigni, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 7, 2014
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health ServiceUmberto Restelli, Massimo Andreoni, Andrea Antinori, et al.
Insights Into Imaging|February 25, 2014
Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessmentGiovanni Mauri, Emanuele Porazzi, Luca Cova, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinicoeconomics and Outcomes Research : CEOR|August 20, 2016
Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectivesDavide Croce, Marzia Bonfanti, Umberto Restelli
Global & Regional Health Technology Assessment|April 1, 2025
Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, et al.
Clinicoeconomics and Outcomes Research : CEOR|May 23, 2023
Co-Design as Enabling Factor for Patient-Centred Healthcare: A Bibliometric Literature ReviewSofia Silvola, Umberto Restelli, Marzia Bonfanti, et al.
Global & Regional Health Technology Assessment|May 22, 2025
Alessandro Tedesco, Marzia Bonfanti, Asia Barugolo, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 24, 2016
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in ItalyUmberto Restelli, Alfredo Alberti, Adriano Lazzarin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 25, 2020
Cost of illness of Primary Biliary Cholangitis - a population-based studyAlessio Gerussi, Umberto Restelli, Davide Croce, et al.
Therapeutics and Clinical Risk Management|July 20, 2017
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsUmberto Restelli, Giuliano Rizzardini, Andrea Antinori, et al.
Journal of Market Access & Health Policy|August 27, 2025
Pivotal Studies for Drugs About to Be Launched for Rare Diseases: Will They Better Support Health Technology Assessment and Market Access than in the Past?Claudio Jommi, Marzia Bonfanti, Melissa Guardigni, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 7, 2014
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health ServiceUmberto Restelli, Massimo Andreoni, Andrea Antinori, et al.
Insights Into Imaging|February 25, 2014
Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessmentGiovanni Mauri, Emanuele Porazzi, Luca Cova, et al.
Pageof 2